As Sangamo Biosciences (SGMO) Share Price Declined, Holder Opaleye Management Has Cut by $855,000 Its Holding; As Alibaba Group Holding (BABA) Stock Rose, Northern Cross Has Lowered Position

June 13, 2018 - By Adrian Mccoy

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Northern Cross Llc decreased its stake in Alibaba Group Holding (BABA) by 23.57% based on its latest 2018Q1 regulatory filing with the SEC. Northern Cross Llc sold 1.42 million shares as the company’s stock rose 2.58% while stock markets declined. The institutional investor held 4.60M shares of the business services company at the end of 2018Q1, valued at $844.75 million, down from 6.02 million at the end of the previous reported quarter. Northern Cross Llc who had been investing in Alibaba Group Holding for a number of months, seems to be less bullish one the $534.48B market cap company. The stock decreased 0.51% or $1.07 during the last trading session, reaching $208.01. About 7.22M shares traded. Alibaba Group Holding Limited (NYSE:BABA) has risen 61.13% since June 13, 2017 and is uptrending. It has outperformed by 48.56% the S&P500. Some Historical BABA News: 20/04/2018 – Alibaba buys Chinese chipmaker to aid internet of things business after ZTE ban; 19/03/2018 – Alibaba invests another $2bn in south-east Asia’s Lazada; 19/03/2018 – ADRs End Lower; Baidu, Alibaba, BP Trade Actively; 25/05/2018 – US News: China to Use Cornerstones to Help Alibaba, Xiaomi List in Mainland; 12/04/2018 – U.S. Spatial-Analytics Firm Esri, Alibaba Cloud Entered Into Collaborative Agreement; 02/04/2018 – Alibaba files trademark lawsuit against Dubai firm behind ‘Alibabacoin’; 06/03/2018 – SAIC TO DEEPEN COOPERATION WITH ALIBABA ON CAR-SHARING PLATFORM; 19/03/2018 – Alibaba Bets Another $2 Billion on Southeast Asia; 14/05/2018 – China tech giants bet on untangling logistics of Indonesian e-commerce; 13/03/2018 – Chinese bike-sharing firm Ofo has raised $866 million in new funding led by Alibaba

James A. Silverman decreased its stake in Sangamo Biosciences Inc (SGMO) by 7.76% based on its latest 2018Q1 regulatory filing with the SEC. Opaleye Management Inc sold 45,000 shares as the company’s stock declined 37.47% with the market. The hedge fund run by James A. Silverman held 535,000 shares of the health care company at the end of 2018Q1, valued at $10.17 million, down from 580,000 at the end of the previous reported quarter. Opaleye Management Inc who had been investing in Sangamo Biosciences Inc for a number of months, seems to be less bullish one the $1.59B market cap company. The stock decreased 1.42% or $0.225 during the last trading session, reaching $15.625. About 808,678 shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 100.00% since June 13, 2017 and is uptrending. It has outperformed by 87.43% the S&P500. Some Historical SGMO News: 17/04/2018 – SANGAMO THERAPEUTICS – INVESTIGATION DID NOT REVEAL ANY EVIDENCE THAT CO’S NETWORK OR OTHER INFORMATION TECHNOLOGY SYSTEMS WERE OTHERWISE COMPROMISED; 17/04/2018 – SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE’S COMPANY EMAIL ACCOUNT; 16/05/2018 – BIOVERATIV, SANGAMO CITE GENE-EDITED CELL THERAPY BIVV003; 17/04/2018 – SANGAMO THERAPEUTICS: CONFIDENTIAL, SENSITIVE INFO ACCESSED; 30/04/2018 – Sangamo Therapeutics Announces Completion of Public Offering of Common Stk; 24/04/2018 – SANGAMO THERAPEUTICS – SEES USING NET PROCEEDS FROM OFFERING TO SUPPORT OWN, PARTNERED GENE THERAPY, GENOME EDITING, CELL THERAPY, AMONG OTHER THINGS; 08/05/2018 – SANGAMO 1Q LOSS/SHR 23C, EST. EPS 25C; 23/04/2018 – DJ Sangamo Therapeutics Inc, Inst Holders, 1Q 2018 (SGMO); 16/05/2018 – Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease; 24/04/2018 – SANGAMO THERAPEUTICS TO OFFER $200.0M OF SHRS

Northern Cross Llc, which manages about $51.96 billion and $6.09 billion US Long portfolio, upped its stake in Teva Pharmaceutical (NYSE:TEVA) by 2.30 million shares to 24.50M shares, valued at $418.69M in 2018Q1, according to the filing.

Analysts await Alibaba Group Holding Limited (NYSE:BABA) to report earnings on August, 16. They expect $1.16 EPS, up 23.40% or $0.22 from last year’s $0.94 per share. BABA’s profit will be $2.98B for 44.83 P/E if the $1.16 EPS becomes a reality. After $0.54 actual EPS reported by Alibaba Group Holding Limited for the previous quarter, Wall Street now forecasts 114.81% EPS growth.

More notable recent Alibaba Group Holding Limited (NYSE:BABA) news were published by: Seekingalpha.com which released: “Ant Financial raises $14B ahead of IPO” on June 08, 2018, also Seekingalpha.com with their article: “Buy Alibaba – Cramer’s Lightning Round (6/12/18)” published on June 13, 2018, Seekingalpha.com published: “Alibaba: The Battle Enters Decisive Point” on May 27, 2018. More interesting news about Alibaba Group Holding Limited (NYSE:BABA) were released by: Finance.Yahoo.com and their article: “Alibaba Group Holding Ltd Is Riding This Catalyst to New Highs” published on June 07, 2018 as well as Fool.com‘s news article titled: “4 Important Updates About Alibaba’s Cainiao Logistics Network” with publication date: June 12, 2018.

Among 39 analysts covering Alibaba (NYSE:BABA), 37 have Buy rating, 1 Sell and 1 Hold. Therefore 95% are positive. Alibaba had 182 analyst reports since August 12, 2015 according to SRatingsIntel. M Partners maintained Alibaba Group Holding Limited (NYSE:BABA) on Wednesday, August 26 with “Buy” rating. The stock of Alibaba Group Holding Limited (NYSE:BABA) earned “Buy” rating by Oppenheimer on Tuesday, August 22. The stock of Alibaba Group Holding Limited (NYSE:BABA) has “Outperform” rating given on Wednesday, January 11 by Bernstein. The rating was upgraded by Zacks on Tuesday, September 1 to “Strong Sell”. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, August 15. The firm earned “Buy” rating on Thursday, November 2 by RBC Capital Markets. The company was maintained on Thursday, October 20 by Needham. The stock of Alibaba Group Holding Limited (NYSE:BABA) has “Overweight” rating given on Monday, January 25 by Morgan Stanley. The stock of Alibaba Group Holding Limited (NYSE:BABA) has “Overweight” rating given on Saturday, August 29 by Morgan Stanley. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, August 12 report.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on August, 8. They expect $-0.13 EPS, up 23.53% or $0.04 from last year’s $-0.17 per share. After $-0.23 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -43.48% EPS growth.

Since January 2, 2018, it had 0 insider buys, and 18 insider sales for $2.80 million activity. Another trade for 5,000 shares valued at $85,545 was sold by Conner Edward R.. Mento Steven J also sold $219,546 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares. Herberts Curt A. III sold $163,260 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Friday, April 13. 5,000 shares valued at $127,812 were sold by Yi Kathy on Thursday, March 15.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 27 analyst reports since August 8, 2015 according to SRatingsIntel. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Hold” rating given on Monday, May 21 by Wedbush. The company was downgraded on Wednesday, October 19 by Piper Jaffray. Wedbush maintained it with “Hold” rating and $6.0 target in Wednesday, November 15 report. Wedbush maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Wednesday, September 2 with “Buy” rating. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Neutral” rating given on Wednesday, October 19 by PiperJaffray. The company was initiated on Friday, December 4 by Wells Fargo. The firm earned “Hold” rating on Tuesday, March 13 by Wedbush. On Thursday, June 22 the stock rating was reinitiated by Jefferies with “Buy”. The firm has “Overweight” rating by JP Morgan given on Saturday, August 8. As per Thursday, February 22, the company rating was maintained by Piper Jaffray.

Investors sentiment decreased to 1.24 in 2018 Q1. Its down 0.16, from 1.4 in 2017Q4. It dropped, as 12 investors sold SGMO shares while 62 reduced holdings. 46 funds opened positions while 46 raised stakes. 53.36 million shares or 0.26% more from 53.22 million shares in 2017Q4 were reported. Gru Incorporated One Trading LP holds 85,003 shares or 0.02% of its portfolio. Advisory Network Lc holds 0.01% or 6,288 shares. Art Advsrs Limited Liability Company holds 154,406 shares or 0.12% of its portfolio. Tiaa Cref Investment Limited Liability owns 584,538 shares. Schwab Charles Management stated it has 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Atlantic Trust Gp Ltd Liability has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Weiss Multi has invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Teacher Retirement Of Texas accumulated 18,782 shares. Alliancebernstein LP has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). The New York-based Pdts Ptnrs Ltd Llc has invested 0.29% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Moreover, Asset Mngmt has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Sg Americas Secs Limited Liability Corporation holds 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 9,530 shares. Pub Employees Retirement Sys Of Ohio invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). California Employees Retirement Systems reported 135,062 shares or 0% of all its holdings. Cookson Peirce Communication has invested 0.05% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Opaleye Management Inc, which manages about $151.96 million and $349.75 million US Long portfolio, upped its stake in Fennec Pharmaceuticals Inc by 26,100 shares to 873,000 shares, valued at $10.56 million in 2018Q1, according to the filing. It also increased its holding in Loxo Oncology (NASDAQ:LOXO) by 3,100 shares in the quarter, for a total of 179,400 shares, and has risen its stake in Strongbridge Biopharma Plc.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>